The World of Clinical Trial Development Post COVID-19: Lessons Learned from a Global Pandemic.
Clin Cancer Res
; 26(16): 4198-4200, 2020 08 15.
Article
in English
| MEDLINE | ID: covidwho-535418
ABSTRACT
The novel coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is a global health threat (1). Patients with cancer are one of the most vulnerable populations. During this pandemic, clinical trial accrual to NCI studies has fallen dramatically. Investigators quickly turned to regulatory bodies to simplify treatment schedules, facilitate telemedicine, and decrease required data collection. Going forward, the oncology research community must use the lessons learned to focus on redesigning studies to ensure that critical scientific questions are answered safely while expanding access and increasing partnerships with community physicians. These changes will accelerate clinical progress while protecting our patients.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Clinical Trials as Topic
/
Coronavirus Infections
/
Pandemics
/
Betacoronavirus
/
Medical Oncology
/
Neoplasms
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Topics:
Long Covid
Limits:
Humans
Country/Region as subject:
North America
Language:
English
Journal:
Clin Cancer Res
Journal subject:
Neoplasms
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS